Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review

  • ID: 1936302
  • SWOT Analysis
  • 57 pages
  • GlobalData
  • Dr Reddy’s Laboratories Ltd
1 of 5

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Cipla Ltd
  • Eli Lilly and Co
  • IPCA Laboratories Ltd
  • MSN Laboratories Pvt Ltd
  • Novartis AG
  • MORE
Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.

Dr. Reddy's Laboratories Ltd Key Recent Developments

Jul 20, 2018: Dr. Reddy’s announces the launch of Esomeprazole magnesium delayed-release capsules USP, 20 mg in the U.S. market
Jun 28, 2018: Dr. Reddy's Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1
Jun 28, 2018: Indivior's Temporary Restraining Order is Extended
Jun 14, 2018: Dr. Reddy's Announces Resignation of Hans Peter Hasler As Independent Director
Jun 03, 2018: Dr Reddy's API Srikakulam plant gets USFDA nod

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Cipla Ltd
  • Eli Lilly and Co
  • IPCA Laboratories Ltd
  • MSN Laboratories Pvt Ltd
  • Novartis AG
  • MORE
Section 1 - About the Company
  • Dr. Reddy's Laboratories Ltd - Key Facts
  • Dr. Reddy's Laboratories Ltd - Key Employees
  • Dr. Reddy's Laboratories Ltd - Key Employee Biographies
  • Dr. Reddy's Laboratories Ltd - Major Products and Services
  • Dr. Reddy's Laboratories Ltd - History
  • Dr. Reddy's Laboratories Ltd - Company Statement
  • Dr. Reddy's Laboratories Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Dr. Reddy's Laboratories Ltd - Business Description
  • Business Segment: Global Generics
  • Overview
  • Performance
  • Business Segment: Others
  • Overview
  • Performance
  • Business Segment: Pharmaceutical Services & Active Ingredients
  • Performance
  • Business Segment: Pharmaceutical Services and Active Ingredients (PSAI)
  • Overview
  • Business Segment: Proprietary Products
  • Overview
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Russia
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Dr. Reddy's Laboratories Ltd - Corporate Strategy
  • Dr. Reddy's Laboratories Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Dr. Reddy's Laboratories Ltd - Strengths
  • Dr. Reddy's Laboratories Ltd - Weaknesses
  • Dr. Reddy's Laboratories Ltd - Opportunities
  • Dr. Reddy's Laboratories Ltd - Threats
  • Dr. Reddy's Laboratories Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Dr. Reddy's Laboratories Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 20, 2018: Dr. Reddy’s announces the launch of Esomeprazole magnesium delayed-release capsules USP, 20 mg in the U.S. market
  • Jun 28, 2018: Dr. Reddy's Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1
  • Jun 28, 2018: Indivior's Temporary Restraining Order is Extended
  • Jun 02, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant
  • May 22, 2018: Dr. Reddy’s Q4 and FY18 Financial Results
  • Mar 29, 2018: Dr. Reddy's Laboratories announces Senior Leadership Changes
  • Mar 16, 2018: Dr.Reddy's Laboratories Announces Launch Of Levocetirizine Dihydrochloride Tablets USP, 5mg In U.S. Market
  • Mar 16, 2018: Dr. Reddy's Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana
  • Feb 25, 2018: Dr. Reddy’s Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India
  • Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Dr. Reddy's Laboratories Ltd, Key Facts
  • Dr. Reddy's Laboratories Ltd, Key Employees
  • Dr. Reddy's Laboratories Ltd, Key Employee Biographies
  • Dr. Reddy's Laboratories Ltd, Major Products and Services
  • Dr. Reddy's Laboratories Ltd, History
  • Dr. Reddy's Laboratories Ltd, Subsidiaries
  • Dr. Reddy's Laboratories Ltd, Joint Venture
  • Dr. Reddy's Laboratories Ltd, Key Competitors
  • Dr. Reddy's Laboratories Ltd, Ratios based on current share price
  • Dr. Reddy's Laboratories Ltd, Annual Ratios
  • Dr. Reddy's Laboratories Ltd, Annual Ratios
  • Dr. Reddy's Laboratories Ltd, Annual Ratios
  • Dr. Reddy's Laboratories Ltd, Interim Ratios
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Dr. Reddy's Laboratories Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Dr. Reddy's Laboratories Ltd, Performance Chart (2014 - 2018)
  • Dr. Reddy's Laboratories Ltd, Ratio Charts
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Surya Pharmaceutical Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Patheon Inc
  • Novartis AG
  • Mylan Laboratories Ltd
  • MSN Laboratories Pvt Ltd
  • Lonza Group Ltd
  • IPCA Laboratories Ltd
  • Gufic BioSciences Ltd
  • Eli Lilly and Co
  • Divi's Laboratories Ltd
  • Dishman Pharmaceuticals and Chemicals Ltd
  • Cipla Ltd
  • Cadila Pharmaceuticals Ltd
  • Bliss GVS Pharma Ltd
  • Aurobindo Pharma Ltd
  • Albany Molecular Research Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll